Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Phillips 66 (PSX) Price & Performance

Merck & Co., Inc.Trade
Phillips 66Trade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Phillips 66 — how do they compare? Merck & Co., Inc. trades at $133.06 (market cap $321.77B), while Phillips 66 trades at $223.67 (market cap $89.52B). The key difference: Merck & Co., Inc. is far larger — about 3.6× Phillips 66's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

MRKPSX
Market Cap
$321.77B$89.52B
Sector
HealthEnergy
52-Week High
$131.84$224.36
52-Week Low
$77.60$120.04
Enterprise Value
$368.53B$105.99B
Dividend Yield
2.61%2.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Phillips 66

Phillips 66 (PSX) trades at $215.52, up 5.69% in the last session, reflecting strong momentum. The stock exhibits bullish technical signals with key support at $208 and resistance at $219. Fundamentally, Q2 2026 EPS of $9.41 significantly beat estimates, driven by robust refining margins and high utilization rates. Recent news highlights the final investment decision for the $5 billion Western Gateway Pipeline joint venture, signaling growth in midstream operations.

Outlook remains positive with analyst consensus favoring Buy ratings (57%) and a $221.92 price target. Key opportunities include sustained refining strength and debt reduction, while risks involve volatile crude prices and geopolitical tensions affecting supply chains. Earnings growth and strategic projects underpin potential upside, but investors should monitor margin pressures and global energy dynamics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Phillips 66

Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.

Read more on PSX